USE OF ELSIGLUTIDE TO TREAT GASTROINTESTINAL MUCOSITIS INCLUDING CHEMOTHERAPY-INDUCED DIARRHEA

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20160067311A1
SERIAL NO

14842250

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to the use of elsiglutide to prevent or reduce the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZEALAND PHARMA A/SSYDMARKEN 11 SØBORG 2860

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
CALCAGNILE, Selma Appiano Gentile (como), IT 1 1
GIORGINO, Ruben Allschwil, CH 8 4
MORESINO, Cecilia Morbio Inferiore, CH 1 1
RONCORONI, Simona Villa Guardia (como), IT 1 1
SPEZIA, Riccardo Milano, IT 1 1
TRENTO, Fabio Colverde, IT 12 41

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation